NEXT GENERATION ANTIBODY THERAPEUTICS
Improving antibody directed delivery of cargo
OUR BUSINESS
iProgen has developed a proprietary and powerful antibody delivery technology platform which can be used to design innovative first-in-class drugs for unmet medical needs.
​
Our goal is to advance select drug candidates into clinical development to demonstrate the benefits of our technology platform and fostering broad industry adoption.
Technology application
ANTIBODY DRUG CONJUGATE
A critical factor in developing a successful Antibody Drug Conjugate (ADC) is the antibody’s ability to internalize once it binds to the cancer cell’s target-receptor. Although some cancer cell-specific receptors internalize the antibody efficiently following binding (e.g. EGFR2), many cancer cell receptors (e.g. CD20) do not internalize antibodies efficiently.
iProgen has developed a proprietary antibody engineering technology that enhances antibody delivery and internalization. When this technology was applied to ADC, it has shown a significant improvement in in-vivo efficacy in several mouse xenograft models.
GET IN TOUCH
